Abstract
We report the impact of pulmonary hypertension (PH) on patients undergoing transcatheter valve replacement (TAVR), evaluating the interaction of PH due to primary lung disease. A retrospective cohort study was performed on patients who underwent TAVR from 2010 to 2015 from the TVT registry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
